Mazdutide
Dual GLP-1/glucagon receptor agonist
A dual GLP-1 and glucagon receptor agonist referenced in emerging metabolic-research literature.
Also referenced as: IBI362, LY3305677
Overview
An investigational dual agonist targeting the GLP-1 and glucagon receptors, developed by Eli Lilly and licensed to Innovent Biologics for the Chinese market (also known as IBI362 or LY3305677). It has been evaluated in clinical trials in the 2020s.
At a glance
What Mazdutide does
Mazdutide is a dual GLP-1/glucagon receptor agonist, derived from the oxyntomodulin peptide sequence and engineered for once-weekly dosing. This receptor pairing differs from tirzepatide's GIP/GLP-1 profile: mazdutide combines GLP-1 agonism with glucagon-receptor agonism. The GLP-1 arm supplies glucose-dependent insulin secretion, glucagon suppression at the beta/alpha-cell level, slowed gastric emptying, and central appetite reduction, while the added glucagon-receptor activity raises energy expenditure and promotes hepatic lipolysis and fat mobilization — so like retatrutide it is designed to combine reduced intake with increased energy burn, though as a dual rather than triple agonist. The glucagon component also has direct effects on liver metabolism that are of interest for hepatic fat.
Mazdutide has been developed largely through trials in Chinese populations (the GLORY program in obesity and DREAMS in type 2 diabetes). Reported phase 2/3 results show meaningful weight loss — on the order of low-to-mid teens percent at higher doses in obesity trials — together with HbA1c reductions in diabetes studies and observed reductions in liver fat and improvements in lipids and blood pressure, consistent with the glucagon-driven metabolic effects. Some reports also note reductions in waist circumference and, of interest, effects on serum uric acid. Mazdutide is investigational globally, with its most advanced evidence being human trials concentrated in China; broader long-term and cardiovascular-outcome data are still developing. Its distinguishing feature in this catalog is being the oxyntomodulin-based GLP-1/glucagon dual agonist.
Effects reported in research
- Dual GLP-1 and glucagon receptor agonism from an oxyntomodulin-based peptide (mechanistic / human clinical).
- Meaningful body-weight reduction (roughly low-to-mid teens percent at higher doses) in the GLORY phase 2/3 obesity trials (human clinical).
- HbA1c reductions in type 2 diabetes participants in the DREAMS program (human clinical).
- Increased energy expenditure and hepatic fat mobilization via glucagon-receptor agonism (mechanistic / human clinical).
- Reduced liver fat content reported in trial imaging (human clinical).
- Improved lipid profile and blood pressure alongside weight loss (human clinical).
- Reported reductions in serum uric acid and waist circumference (human clinical).
- Evidence concentrated in Chinese trial populations; global long-term and cardiovascular data still developing (investigational).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Mazdutide is a synthetic peptide agonist that activates both the GLP-1 and glucagon receptors, structurally based on the glucagon/oxyntomodulin family. GLP-1 agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, while glucagon-receptor agonism is proposed to increase energy expenditure and influence hepatic lipid metabolism. The combined activity is being studied for effects on body weight and metabolic parameters.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Mazdutide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Investigational dual GLP-1/glucagon receptor agonist derived from the glucagon/oxyntomodulin peptide family
- Adds glucagon-receptor agonism, hypothesized to increase energy expenditure alongside appetite suppression
- Administered once weekly by subcutaneous injection in reported trials
- Developed by Eli Lilly and advanced by Innovent Biologics (as IBI362) particularly in China
- Distinct from GIP-containing agonists by targeting glucagon rather than GIP
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Mazdutide is a research compound.
In the clinical literature mazdutide is administered once weekly with a stepwise escalation over several weeks. These are reference figures describing published research/protocols, not dosing guidance for humans.
- 9 mg cohort escalation: 3 mg (wk 1-4) -> 6 mg (wk 5-8) -> 9 mg (wk 9-12)
- 10 mg cohort escalation: 2.5 -> 5 -> 7.5 -> 10 mg over ~16 weeks
- Phase 3 (GLORY-1) maintenance references: 4 mg and 6 mg once weekly
Acylated oxyntomodulin analogue engineered for weekly dosing; precise half-life less consistently reported. Investigational compound. Reference figures for research context only.
How it compares
Mazdutide differs from tirzepatide by pairing GLP-1 with glucagon-receptor agonism (rather than GIP), and from single GLP-1 agonists by its dual-receptor action.
Commonly studied alongside
Compounds frequently researched together with Mazdutide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for Mazdutide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Mazdutide sits in the GLP-1 Family area of the PeptiDex library.
- Entry type: Research compound reference
- GLP-1 Family category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source Mazdutide
For researchers studying Mazdutide, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.
PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.
Frequently asked questions
What is mazdutide and what receptors does it target?
Mazdutide (IBI362 / LY3305677) is a once-weekly dual agonist based on a mammalian oxyntomodulin analogue that activates both the GLP-1 and glucagon receptors. The glucagon-receptor arm — associated in research with increased energy expenditure and hepatic fat effects — distinguishes it from GLP-1 mono-agonists. It is studied in obesity and metabolic models, with much of the clinical work conducted in Chinese populations.
How is mazdutide dose-escalated in the research literature?
Reported protocols escalate weekly — for example a 9 mg cohort using 3 mg (weeks 1-4), 6 mg (weeks 5-8), then 9 mg (weeks 9-12), and a 10 mg cohort stepping 2.5 -> 5 -> 7.5 -> 10 mg over 16 weeks. Phase 3 (GLORY-1) work centered on 4 mg and 6 mg weekly maintenance doses. These are reference figures for research context only, not human dosing guidance.
How does mazdutide differ from tirzepatide?
Both are dual agonists, but mazdutide pairs GLP-1 with glucagon-receptor activity, whereas tirzepatide pairs GLP-1 with GIP-receptor activity. The glucagon arm is the mechanistic feature researchers study for its effects on energy expenditure and hepatic fat. Mazdutide is earlier in development and less broadly characterized.
What does mazdutide's dosing schedule imply for study design?
Mazdutide is administered once weekly with a multi-week escalation, consistent with a half-life-extended acylated peptide suited to weekly dosing. Protocols therefore include several weeks of titration before maintenance-phase readouts. Precise half-life figures are less consistently reported in the literature than for semaglutide or tirzepatide.
Is mazdutide an approved drug?
Mazdutide is a late-stage investigational compound (with phase 3 data reported, notably in China) and is not a globally approved medicine in the general research-catalog context. It should be handled strictly as a research chemical, not for human use.
What documentation should be expected for research-grade mazdutide?
A third-party COA with HPLC purity (commonly greater than or equal to 98%) and mass-spec identity confirmation is the standard reference. Lyophilized material is stored cold and reconstituted with bacteriostatic water, protected from light and freeze-thaw cycles.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Primary literature indexed in PubMed for Mazdutide. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.